Sanofi Ventures has led a $17m investment in Click Therapeutics, which develops software to treat medical conditions such as depression, insomnia, acute coronary syndrome and chronic pain, via a mobile app prescribed by doctors. Click is seeking clearance from the US Food and Drug Administration (FDA) to sell the products as class 2 medical devices. The company says it will use its new funding to develop an “innovative platform for delivering personalized medicine based on patient data that can be used across multiple healthcare systems”.
Sanofi Ventures has led a $17m investment in Click Therapeutics, which develops software to treat medical conditions such as depression, insomnia, acute coronary syndrome and chronic pain, via a mobile app prescribed by doctors. Click is seeking clearance from the US Food and Drug Administration (FDA) to sell the products as class 2 medical devices. Last September, Pear Therapeutics received FDA clearance for its reSET software, used to treat substance misuse, while Akili Interactive Labs is seeking FDA clearance for video games to assess and treat attention deficit hyperactivity disorder in children.